Clinical Trials Logo

Safety and Efficacy clinical trials

View clinical trials related to Safety and Efficacy.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06244537 Not yet recruiting - Safety and Efficacy Clinical Trials

Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer

UNLACC
Start date: February 29, 2024
Phase: N/A
Study type: Interventional

In this phase I single-arm clinical study, 20 patients with T4b unresectable locally advanced colon cancer are proposed to be enrolled, who will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX. The study will assess patients' surgical R0 resection rate, pCR or cCR rate, PFS, OS, and related adverse effects of treatment, aiming to explore the feasibility, safety, and efficacy of MR-Linac in the treatment of unresectable locally advanced colon cancer.

NCT ID: NCT05008666 Not yet recruiting - Safety and Efficacy Clinical Trials

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

ENKTL is a highly aggressive non-Hodgkin lymphoma closely related to EBV infection,and advanced patients often suffer from hemophagocytic lymphohistiocytosis (HLH). ENKTL-HLH lacks standard treatment and experiences a extremely poor prognosis. Anti-PD-1 antibody has shown good anti-tumor activity in ENKTL and play a potential role in EBV-HLH. Epigenetic drugs have been confirmed to exert synergistic anti-tumor activity with anti-PD-1 antibody. We next further explore the efficacy and safety of Sintilimab sequential combination of epigenetic drugs in ENKTL-HLH.